Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy
This article provides perspectives on the use of Cerebrolysin as an adjunct treatment to reperfusion therapy in acute ischemic stroke (AIS). In the evolving landscape of AIS reperfusion therapy, we hypothesize that adjunctive cerebroprotective the...
Ribó M, Staszewski J, Zeiler SR et al. — Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study
Stroke-induced aphasia significantly impacts communication and quality of life. Despite the standard treatment being speech and language therapy, outcomes vary, highlighting the need for additional therapies. Cerebrolysin, a neuroprotective and ne...
Homberg V, Jianu DC, Stan A et al. — Stroke
Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study
This study hypothesized that Cerebrolysin, a multimodal neuroprotective agent, enhances the efficacy and safety of mechanical thrombectomy (MT) in both acute ischemic stroke (AIS) and recovery stroke phases in selected patients with good collatera...
Staszewski J, Dębiec A, Strilciuc S et al. — Translational stroke research
C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke
The main objective of the Cerebrolysin REGistry Study in Stroke 2 (C-REGS2) was to systematically record the routine clinical use of Cerebrolysin in patients with moderate ischemic stroke (IS) following the principles of a prospective controlled e...
Vosko MR, Sanak D, Do Y et al. — International journal of stroke : official journal of the International Stroke Society
Life-Threatening Anaphylaxis due to Cerebrolysin®
In this case report, we describe a well-documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids....
Trimmel H, Tauber W, Zikeli M — Case reports in neurological medicine
Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
Parkinson's disease (PD) is affecting >10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About ...
Ozkizilcik A, Sharma A, Lafuente JV et al. — Progress in brain research
Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease
Alzheimer's disease (AD) is estimated to be afflicting over 55 millions of individual worldwide in 2018-19 for which no suitable clinical therapeutic measures have been developed so far. Thus, there is an urgent need to explore novel therapeutic s...
Sharma HS, Muresanu DF, Castellani RJ et al. — Progress in brain research
[Cerebrolysin for acute ischemic stroke]
The review discusses existing evidence of benefits and risks of cerebrolysin--a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue with proposed neuroprotective and neurotrophic properties, for acute ischemic ...
iganshina LE, Abakumova TR — Vestnik Rossiiskoi akademii meditsinskikh nauk
Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials
The safety of Cerebrolysin has been shown through many years of clinical use, observations from postmarketing surveillance studies, and safety data from randomized, controlled clinical trials. The reported events showed that adverse reactions to C...
Thome J, Doppler E — Drugs of today (Barcelona, Spain : 1998)
Spotlight on cerebrolysin in dementia
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration ...
Plosker GL, Gauthier S — CNS drugs